GlyTR Therapeutics ‘Cancer Moonshot’ Technology Receives Second Grant from the National Cancer Institute

“The funding of these two grants provides scientific validation of GlyTR technology and its potential to greatly broaden cancer immunotherapy to the vast majority common cancers,” says Bob Genthert, an EvoNexus mentor-in-residence and GlyTR Therapeutics’ board member and investor. “This is testament to the herculean efforts that Professor Michael Demetriou MD, Ph.D. and post-doctoral fellow, Raymond Zhou, Ph.D. have put into the discovery of GlyTR technology at the University of California, Irvine.”